01 — Evidence
Evidence Summary
The honest headline is a mismatch. Dandelion — chiefly aqueous root extract — has a genuine preclinical record: it kills cancer cells while sparing the non-cancer cells tested, repeated across several cancer models — much of it a sustained research programme by a University of Windsor group that has taken a particular interest in dandelion root and studied it across cancer types. No controlled human oncology trial has shown it works; the human record is uncontrolled case reports. And because the species, the plant part and the solvent all change the result, evidence cannot be moved freely between preparations. Every finding below sits at the preclinical tier.
Human
Clinical Record
No controlled trial — a case report + non-oncology data
No controlled human trial has shown dandelion affects a tumour. The published human oncology record is a single uncontrolled case report; the rest of the human evidence is non-oncology pharmacology and safety data.
- No controlled, results-bearing human oncology trial has demonstrated an anticancer effect
- The one published oncology report is a CMML case taking dandelion root plus papaya leaf — uncontrolled, two products at once
- Human diuretic and safety studies exist, but say nothing about cancer
Animal
Preclinical Signal
Oral xenografts across several cancers
Oral root extract shrank tumours in mouse models of colorectal, esophageal and prostate cancer, and dandelion extract reduced lung metastasis in a breast-cancer model.
- Oral root extract cut colon-cancer xenograft growth by more than 90%
- Reduced lung metastasis and cancer-stem-cell markers in a breast-cancer model
- The constituent taraxasterol shrank liver tumours while raising tumour T-cell infiltration
In Vitro
Cell Model Data
Selective killing; part- and solvent-dependent
Aqueous root extract's most reproduced finding is selective apoptosis — it triggered cancer-cell death through early caspase-8 while sparing normal cells, across leukemia, pancreatic, colorectal and melanoma lines.
- Killed cancer cells while sparing the non-cancer comparator cells tested (blood cells, colonocytes, fibroblasts)
- Leaf extract slowed a breast line and blocked invasion; flower extract did neither
- A related-species (T. mongolicum) alcoholic extract instead stimulated ER-positive breast-cell growth
Human
Clinical Record
Dandelion has no controlled human oncology evidence, but the record is not entirely empty: there is a peer-reviewed case report in a blood cancer, plus a small body of human non-oncology pharmacology — mostly on its traditional diuretic use. None of it establishes an anticancer effect, and the honest conclusion is that no controlled, results-bearing human trial has shown dandelion to work.
Continue reading — full research detail+
The published human oncology evidence is a single uncontrolled case report: a 76-year-old with previously untreated chronic myelomonocytic leukemia whose blood counts remained stable and marrow blast counts improved while taking dandelion root extract together with papaya leaf extract.[37] The intervention was uncontrolled and used two natural products at once, so it cannot show that dandelion caused the outcome. It is enough to make “no human oncology data of any kind” inaccurate, but nowhere near enough to demonstrate efficacy — and it is the extent of the published oncology record, not a trial result.
The non-oncology human data actually reinforce this page's central point that the preparation matters. A fresh-leaf hydroethanolic T. officinale extract significantly increased urination frequency in a 17-person pilot,[38] while a 2026 crossover study found a commercial T. officinale root powder produced no additional urine output over water alone in 14 active adults.[39] A hydroethanolic leaf extract and a commercial root powder are simply not the same intervention — and neither tells us anything about cancer.
The rest of the human record is safety-side: dandelion is a recognised Asteraceae contact allergen,[33,34] and regulators caution against dandelion root in biliary disease because of its choleretic action.[41] Its blood-glucose-lowering reputation rests mainly on in-vitro DPP-IV inhibition and on multi-herb formulations, not on dandelion alone.[35]
Signal maturity: no controlled human oncology data. The human evidence is a single uncontrolled case report plus non-oncology pharmacology — enough to show that different dandelion preparations behave differently, nowhere near enough to show an anticancer benefit.
Animal
Preclinical Signal
Across several tumour models, orally-administered dandelion root extract slowed tumour growth while the animals tolerated it — the preclinical signal is real and selective, though much of the strongest work comes from a single research group.[5,6,7]
Continue reading — full research detail+
Oral aqueous root extract retarded a human colon-cancer xenograft by more than 90%, killing cancer cells through multiple death pathways irrespective of their p53 status.[5] In esophageal squamous-cell carcinoma, oral root extract slowed xenograft growth while lowering PI3K/Akt and Ras/Raf/ERK signalling.[6] In prostate cancer, dandelion root extract and lemongrass extract were tested as separate treatments, and each reduced xenograft burden after oral administration; in cells, the root extract significantly enhanced mitoxantrone-induced apoptosis but did not significantly affect taxol.[7]
A T. mongolicum extract also reduced lung metastasis and cancer-stem-cell markers in a triple-negative breast-cancer model,[9] and among the constituents, taraxasterol shrank liver-cancer and hepatocellular-carcinoma xenografts — in one case while increasing CD4 T-cell infiltration into the tumour.[13,14] A dandelion polysaccharide–selenium construct inhibited tumour growth and blood-vessel formation in zebrafish embryos.[20] Separately — and directly on the labelled species — an aqueous fermented T. officinale extract was more toxic to a panel of paediatric cancer lines than to normal fibroblasts, inducing apoptosis and reduced invasion in neuroblastoma cells.[24]
Two cautions temper this. Much of the deepest root-extract work — leukemia, pancreatic, colorectal, melanoma — comes from a single research group, so the signal is repeated across models rather than independently replicated with one characterised preparation.[1,2,4,5] And breadth is not universal: in a head-to-head herb comparison, a T. mongolicum preparation (a different species from the aqueous root work) did not reduce the viability of an AGS gastric-cancer line while two other herbs did — though the constituent taraxasterol did suppress a gastric-cancer line via glycolysis in a separate study, so the gastric picture is preparation- and species-dependent.[31,25]
Signal maturity: repeated across several cancer models and oral-dosed, with corroboration from separate laboratories for esophageal, breast and the constituent studies — but entirely preclinical, spread across several Taraxacum species and preparations, and with at least one clearly negative cancer type.
In Vitro
Cell Model Data
Dandelion's deepest finding is that aqueous root extract kills cancer cells while sparing the non-cancer comparator cells tested. In the leukemia/CMML and melanoma work the trigger is early caspase-8/FADD-dependent (extrinsic) death; in pancreatic and colorectal models the extract engages mitochondrial and multiple other death pathways instead. Species, plant part and solvent all change the result.
Continue reading — full research detail+
The clearest death-receptor evidence is in the blood-cancer work: in leukemia (Jurkat), chronic myelomonocytic leukemia and melanoma cells, aqueous root extract activated initiator caspase-8 very early, and cells unable to assemble the death-inducing signalling complex (dominant-negative FADD) were resistant — supporting an upstream extrinsic/DISC-associated mechanism rather than identifying one specific death receptor as the target; the non-cancer comparators (blood mononuclear cells) were spared at the same doses.[1,2,3] The mechanism is not uniform across cancers: pancreatic cancer showed mitochondrial-membrane collapse with prodeath autophagy, and colorectal work explicitly demonstrated multiple death-signalling pathways rather than one death-receptor route.[4,5]
Species, part and solvent are decisive. In one T. officinale study comparing leaf, flower and root, the leaf extract slowed breast-cancer-cell growth, the root extract blocked its invasion, and the leaf extract blocked prostate-cell invasion — while the flower extract did none of these, all traced to reduced matrix-metalloproteinase-2/9 and FAK/Src signalling.[8] A fourth part has since been tested: an aqueous seed extract selectively inhibited esophageal-cancer cells and made them more sensitive to cisplatin.[21] Individual constituents reproduce pieces of the picture — taraxasterol across liver, prostate, bladder and lung cancer,[13,15,16,17] taraxinic acid (isolated from T. coreanum) driving leukemia-cell differentiation,[12] and a T. mongolicum leaf polysaccharide inducing liver-cancer-cell apoptosis[11] — but an isolated compound reaching a tumour is a separate question from an oral extract doing so.
One line points the other way, and it comes largely from a different species. An ethanolic T. mongolicum extract behaved as a phytoestrogen, stimulating ER-positive breast-cancer-cell proliferation and estrogen-receptor signalling in a tamoxifen-blockable way,[29] and an aqueous T. mongolicum/T. formosanum study raised one ER-positive line's proliferation while suppressing two others.[30] That runs opposite to the pro-apoptotic effect in ER-negative breast cells[10] and the aqueous root work — so the effect in hormone-sensitive tissue is species-, preparation- and receptor-status-dependent, and has not been shown for a T. officinale root supplement.
Signal maturity: the caspase-8/FADD apoptosis of root extract is the best-supported killing mechanism, strongest in the blood-cancer work; but effective concentrations are extract-based, the best-studied constituents are poorly soluble, much of the mechanistic breadth is from related species, and the estrogenic counter-signal means “dandelion” is not one uniform actor.
Advertisement
02 — Pathways
Pathway Interaction Profile
Dandelion engages several distinct biological pathways relevant to tumour behaviour, grouped below by the functional role each one supports. Every pathway here is drawn from cell or animal studies — there is no human oncology data — and many are specific to one Taraxacum species, one plant part, one solvent, or one isolated constituent rather than to “dandelion” as a whole; the species is named wherever a study specified it. Direct anti-tumour mechanisms come first, then a separate set supporting the body's own resilience.
Dandelion's Contain evidence concerns keeping cancer from spreading and setting up new sites: reduced invasion and matrix-breakdown machinery, suppression of the cancer-stem-cell state that seeds relapse, and interference with the inflammatory and macrophage signalling a tumour uses to build a supportive niche. Most rests on cell studies, with animal corroboration for the anti-metastatic and stem-cell findings, and much of it is part- or constituent-specific.
Block Seeding & Niche Formation
Research concerning formation of supportive pre-metastatic niches at distant sites.
NF-κB / TNF-α / IL-6 inflammatory axis
A T. mongolicum extract has been reported to disrupt the crosstalk between triple-negative breast-cancer cells and tumour-associated macrophages by lowering RAC2/NF-κB-p65/p38-MAPK inflammatory signalling — reducing TNF-α, IL-1β and IL-6 in the cancer cells, cutting macrophage recruitment and M2 polarisation, and suppressing lung metastasis in a xenograft.[22] The constituent taraxasterol separately lowered IL-6/STAT3 signalling in a liver-tumour model.[14] (Related-species evidence, not shown for T. officinale.)
Angiogenesis / VEGF / HIF-1α
Evidence here is thin and exploratory, and covers only part of the pathway's name. A dandelion inulin-fructan polysaccharide, formulated with selenium nanoparticles, inhibited blood-vessel formation in zebrafish embryos alongside anti-proliferative effects,[20] and an aqueous seed extract lowered VEGF among other metastasis-related proteins in esophageal-cancer cells.[21] There is a weak anti-VEGF/anti-vessel signal but no HIF-1α evidence at all for dandelion, and no mammalian-tumour angiogenesis study — so this axis is carried as exploratory rather than established.
Prevent Tumour Cell Shedding
Research concerning invasion and escape from existing lesions (EMT and ECM breach).
EMT & metastatic invasion
In a T. officinale study comparing leaf, flower and root extracts side by side, the root extract blocked breast-cancer-cell invasion and the leaf extract blocked prostate-cell invasion, both through reduced matrix-metalloproteinase-2/9 activity — while the flower extract did neither.[8] The constituent taraxasterol reproduced this in prostate cancer, cutting invasion, migration and adhesion with lower MMP-2/9 and uPA and higher TIMP-1/2.[15] A T. mongolicum extract also suppressed macrophage-driven EMT and reduced lung metastasis in a breast-cancer xenograft.[22]
Prevent Arrest & Adhesion
Research concerning circulating-tumour-cell arrest, adhesion, and extravasation at distant sites.
Integrin–FAK–Src signaling (focal adhesion)
The anti-invasion effect in the three-part extract comparison was tied mechanistically to decreased phosphorylation of focal-adhesion kinase (FAK) and Src, alongside the matrix-metalloproteinase reductions.[8] In-vitro and from a single study.
Prevent Dormant Reactivation
Research concerning cancer-stem-cell persistence and the reawakening of dormant disease.
Cancer stemness (CD44, ALDH, Nanog/Sox2)
A T. mongolicum extract disrupted cancer-stem-like properties in triple-negative breast cancer — reducing the ALDH-positive fraction, impeding mammosphere formation and lowering SOX2, SOX9, NANOG and FOXM1 — by inhibiting CUEDC2-mediated nuclear β-catenin translocation; a xenograft showed reduced tumour growth, reduced lung metastasis and lower stem-cell markers in vivo.[9] Mechanistically the page's strongest single anti-stemness dataset, though it is a related-species result rather than T. officinale.
Dandelion's Starve evidence is limited and constituent-specific, but real: the triterpene taraxasterol has been reported to suppress tumour glucose metabolism, and a methanolic root extract to switch on the cellular energy sensor AMPK. Two single, unreplicated studies hold this role at partial.
Glucose Axis Pressure
Research concerning tumour glucose uptake, glycolytic flux, and the Warburg phenotype.
Aerobic glycolysis (Warburg effect)
In gastric cancer, taraxasterol suppressed glycolysis — lowering glucose uptake, lactate, LDH activity and ATP — by reducing GPD2, and forcing GPD2 back up reversed both the glycolytic suppression and the anti-tumour effect, supporting a GPD2-dependent mechanism (though rescue does not prove taraxasterol binds GPD2 directly).[25] Separately, a methanolic dandelion root extract raised AMPK phosphorylation in liver-cancer cells, an energy-stress signal that opposes anabolic tumour metabolism.[26] Both are single, unreplicated studies — one constituent-specific (taraxasterol), one solvent-specific (methanolic root) — so this role is held to partial.
Dandelion's Weaken evidence is a spread of pro-survival signalling pathways that root extract and its constituents lower: the PI3K/Akt/mTOR and Ras/Raf/ERK growth axes, STAT3, the Wnt/β-catenin stemness node, and cell-cycle progression. Several are corroborated in animal models; all are preclinical.
Expansion Suppression
Research concerning proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.
PI3K–AKT–mTOR (signaling)
Aqueous root extract produced a dose-dependent reduction of PI3K and phospho-Akt (with Ras/Raf/ERK) directly in esophageal squamous-cell carcinoma, with an oral xenograft effect[6] — the strongest direct-signalling evidence here. A root+leaf fraction associated apoptosis in ER-negative breast cells with PI3K-Akt through proteomic pathway-enrichment and docking (a pathway association rather than a direct perturbation).[10] An aqueous seed extract likewise lowered PI3K/Akt in esophageal cancer,[21] and the constituent taraxasterol acted against non-small-cell lung cancer through upstream EGFR signalling.[17]
JAK/STAT (STAT3)
Whole-plant ethanol extract suppressed STAT3 in A549 lung-cancer cells, lowering the STAT3-regulated survival proteins Bcl-xL, survivin, c-Myc and Mcl-1.[19] Taraxasterol lowered phospho-STAT3 (with JAK2 and MMP-2/9) while radiosensitising bladder cancer, an effect abolished by COX-2 knockdown,[16] and suppressed IL-6/STAT3 in a liver-tumour model.[14]
RAS–RAF–MEK–ERK (MAPK)
Root extract lowered Ras, Raf and pERK1/2 in esophageal squamous-cell carcinoma alongside the PI3K/Akt reduction, with an oral xenograft effect — engaged jointly with PI3K/Akt rather than as an isolated MAPK-inhibition finding.[6]
Wnt / β-catenin
A T. mongolicum extract inhibited CUEDC2-mediated nuclear β-catenin translocation, lowering OCT4-driven stemness transcription, in triple-negative breast cancer with in-vivo corroboration — the same experiment that anchors the stemness finding under Contain, with β-catenin the node linking the two.[9]
Cell cycle checkpoints (CDK4/6–RB–E2F, G1/S, G2/M)
Taraxasterol induced G0/G1 arrest in liver-cancer cells,[13] a leaf polysaccharide arrested hepatocellular cells in S phase,[11] and taraxinic acid drove HL-60 leukemia cells out of cycle into monocyte/macrophage differentiation with lower c-myc and higher p21/p27.[12] Constituent-level and preclinical.
Dandelion's Attack evidence is its most distinctive: aqueous root extract kills cancer cells selectively, and the trigger sits unusually at the death receptor (caspase-8), with a mitochondrial arm alongside. Constituents add further death routes — ferroptosis and an immune-mediated arm — though every finding is preclinical.
Direct Tumour-Directed Killing
Research concerning regulated tumour-cell death (apoptosis, ferroptosis, necroptosis).
Extrinsic apoptosis (death receptors)
The best-defined mechanism of dandelion root extract, strongest in blood cancers. In leukemia (Jurkat), chronic myelomonocytic leukemia and melanoma cells, aqueous root extract activated initiator caspase-8 very early, and cells unable to assemble the death-inducing signalling complex (dominant-negative FADD) were resistant — supporting an upstream extrinsic/DISC-associated death mechanism, without identifying one specific death receptor as the direct target; the non-cancer comparators (blood mononuclear cells) were spared at the same doses.[1,2,3] Pancreatic and colorectal models instead engage mitochondrial and multiple death pathways (see Intrinsic apoptosis), so this is not one universal death-receptor route across all DRE-sensitive cancers.
Intrinsic apoptosis (mitochondrial / Bcl-2)
A mitochondrial arm runs alongside: root extract collapsed the mitochondrial membrane potential with prodeath autophagy in pancreatic cancer and killed more than 95% of colon-cancer cells (p53-independent), and lowered Bcl-2 while raising Bax in esophageal cancer.[4,5,6] The constituent taraxasterol added a selective intrinsic-apoptosis arm in liver cancer (Hint1/Bax/Bcl-2, oral xenograft) and in pancreatic cancer via MDM2/p53,[13,18] and a leaf polysaccharide induced hepatocellular-cell apoptosis.[11]
Ferroptosis (execution / cell death)
The dandelion triterpene taraxerol induced ferroptosis in breast-cancer cells — raising lipid peroxidation and iron and lowering glutathione — by promoting ubiquitin-mediated degradation of the ferroptosis-defence enzyme GPX4 through the Nrf2/MIB2 axis, with a xenograft effect in vivo.[23] A whole T. mongolicum extract has since been reported to induce ferroptosis in triple-negative breast cancer via NCOA4-mediated ferritinophagy, in vitro and in vivo and selective versus normal breast cells.[42] The extract evidence strengthens the axis, but taraxerol is an isolated compound — reaching a tumour at ferroptotic concentrations from an oral dandelion preparation is a separate, untested question.
Immune-Mediated Killing (Re-enabled)
Research concerning restoration of immune recognition and cytotoxic clearance of tumour cells.
Immune checkpoints & myeloid skewing (M2/MDSC)
Taraxasterol raised the CD4 T-cell ratio and increased T-cell infiltration into a liver tumour.[14] In triple-negative breast cancer, a T. mongolicum extract reduced tumour-associated-macrophage recruitment and shifted macrophages from an M2 toward an M1 phenotype, lowering the immunosuppressive IL-10/STAT3/PD-L1 axis.[22,43] These are T-cell-infiltration and macrophage-polarisation effects; no cited study establishes myeloid-derived-suppressor-cell (MDSC) biology, so that part of the pathway label is not evidenced here. Exploratory, from single constituents and related-species models.
Dandelion's Protect classification has no cancer-patient host-outcome trial; it rests on preclinical host-protection and long traditional use. The two most relevant findings — protection of the gut lining and antioxidant protection of skin cells — are set out below. Each carries a “conflict-check”: a note on whether that host benefit could also work against cancer treatment — for example, an antioxidant that shields healthy cells possibly blunting therapies that rely on oxidative stress.
Oncology Host-Status
No controlled human evidence. There is no cancer-patient host-outcome trial for dandelion. Its Protect classification rests entirely on preclinical host protection and traditional digestive and hepatic use — none of it measured in people during cancer treatment. Nothing here should be read as a demonstrated supportive-care benefit in patients.
GI Integrity & Microbiome
Research concerning gut-barrier integrity, microbiome composition, and host immune regulation.
Colonocyte protection and experimental colitis
Aqueous root extract raised viability and lowered apoptosis in stressed human colonocytes and, in a dextran-sulfate mouse model, reduced weight loss, disease severity, colon shortening, inflammation and oxidative stress by lowering NF-κB and reactive oxygen species — relevant to colonic inflammatory injury, though not evidence that dandelion prevents colorectal cancer.[27] Conflict-check: Independent — normal-tissue/GI protection in an inflammation model, not a demonstration that dandelion preserves any cancer therapy's efficacy; no human data.
Other Organ-System Reserve
Preclinical research on the resilience of organ systems outside the primary tumour site.
Antioxidant tissue protection (leaf and flower)
In one human-fibroblast study, leaf and flower extracts — more than root, the reverse of the anticancer ranking — protected human skin fibroblasts from UVB-induced and peroxide-induced damage and senescence, lowering matrix-metalloproteinase activity and reactive oxygen species (ROS) and raising glutathione.[28] Conflict-check: possible interference, untested — this is the kind of host benefit that can cut both ways. Radiotherapy and several chemotherapies kill tumour cells by raising ROS, so an antioxidant that lowers ROS could in principle blunt them. Whether dandelion's antioxidant effect actually does this during treatment has never been tested, and this was a non-cancer skin-cell model with no human data — so it is neither demonstrated protection nor proven harm, just a real interaction to keep in view.
Prevent Tumour Cell Shedding
Research concerning invasion and escape from existing lesions (EMT and ECM breach).
Root and leaf extracts, and the constituent taraxasterol, reduced cancer-cell invasion and matrix-breaking enzymes in cell studies — the flower extract did not.
Prevent Dormant Reactivation
Research concerning cancer-stem-cell persistence and the reawakening of dormant disease.
Cancer stemness (CD44, ALDH, Nanog/Sox2)
Dandelion extract lowered cancer-stem-cell markers and reduced lung spread in a breast-cancer model, in cells and in mice — the page's clearest anti-metastasis finding.
Glucose Axis Pressure
Research concerning tumour glucose uptake, glycolytic flux, and the Warburg phenotype.
Aerobic glycolysis (Warburg effect)
The constituent taraxasterol curbed cancer-cell sugar metabolism, and a methanolic root extract switched on the energy sensor AMPK — both single, unreplicated studies.
Expansion Suppression
Research concerning proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.
Root extract lowered the PI3K/Akt and Ras/Raf/ERK growth signals in esophageal cancer, with a tumour-shrinking effect in mice.
Direct Tumour-Directed Killing
Research concerning regulated tumour-cell death (apoptosis, ferroptosis, necroptosis).
Extrinsic apoptosis (death receptors)
Aqueous root extract switched on death-receptor (caspase-8) cell death selectively in leukemia and melanoma cells, sparing normal cells. Evidence is preclinical.
GI Integrity & Microbiome
Research concerning gut-barrier integrity, microbiome composition, and host immune regulation.
Colonocyte protection and experimental colitis
Root extract protected the gut lining and eased experimental colitis in mice — a host benefit, not an anticancer effect, and not yet tested in people.
Advertisement
03 — Pharmacokinetics
Pharmacokinetics and Administration
How dandelion behaves in the body is largely uncharacterised: there is no human pharmacokinetic study of its anticancer constituents. What is clear is that its lead actives are poorly soluble, that the plant part and solvent change which constituents are present, and that the concentrations active in a dish are not shown to be reachable by oral use.
Absorption
Dandelion is a whole-plant mixture. Its best-studied anticancer constituents — the triterpenes taraxasterol and taraxerol — are poorly water-soluble, while its inulin fibre is fermented rather than absorbed. No single figure describes “dandelion.”
The Concentration Gap
The anticancer effects use extracts applied directly to cells; no human study shows oral dandelion reaches those concentrations. Encapsulation cut the effective concentration roughly threefold in one liver-cancer study.
Clinical Dose Context
Traditional and supplement doses target digestion and diuresis — hundreds of milligrams to a few grams of dried root or leaf daily — not any oncology endpoint. No cancer-relevant dose is defined.
Formulation Effects
Because the actives are poorly soluble, delivery research is active. Chitosan nanoparticles lowered the effective concentration and raised cancer-cell selectivity of dandelion extract against liver-cancer cells. See the quick guide below for what each preparation is shown to do.
Metabolism
Based on their chemical classes, triterpenes would undergo hepatic metabolism, phenolic acids extensive conjugation, and inulin fermentation to short-chain fatty acids. No dedicated human dandelion metabolite study exists.
Co-Dosing Considerations
Two preclinical signals warrant a treating-team conversation: a theoretical glucose interaction (in-vitro DPP-IV, not established for dandelion alone) and estrogenic activity in related Taraxacum species relevant to hormone-sensitive disease.
| Preparation | What the research shows | Citation |
|---|---|---|
| Aqueous root extract | The apoptosis workhorse — selective caspase-8 killing across blood and GI cancers, with oral xenograft effects | [1,2,4,5] |
| Leaf extract | Slows breast-cell growth and blocks invasion; with flower, the stronger antioxidant host protection | [8,28] |
| Flower extract | Weakest anticancer signal — no growth or invasion effect in the direct comparison; antioxidant | [8,28] |
| Seed extract (aqueous) | Selective anti-esophageal activity and cisplatin chemosensitisation | [21] |
| Alcoholic extract | Carries the estrogenic signal (ethanolic, related Taraxacum species); a methanolic root extract activates AMPK | [29,26] |
| Nanoparticle-encapsulated | Lower effective concentration and higher cancer-cell selectivity in vitro | [32,20] |
Absorption
Dandelion is taken as a whole-plant preparation rather than a single molecule, so absorption is really the absorption of a mixture whose constituents behave very differently. The best-studied isolated anticancer constituents — the triterpenes taraxasterol, taraxerol, lupeol and the amyrins identified in root extract — are lipophilic and poorly water-soluble, and a 2026 delivery study states plainly that dandelion-derived phytochemicals are limited by “poor solubility, instability, and low intracellular bioavailability.”[32] Other constituents behave differently again: the inulin-type fructans and pectic polysaccharides of root and leaf are water-soluble fibre that is largely fermented rather than absorbed intact,[11,20] and the phenolic acids (chicoric, chlorogenic) are absorbed and heavily conjugated like other dietary polyphenols.
The defining fact is an absence of human data: no human pharmacokinetic study measures the plasma levels of dandelion's anticancer constituents after an oral dose. There is some animal pharmacokinetics — an LC-MS/MS assay measured taraxasterol in rat plasma after oral doses of 7.75, 15.5 and 31 mg/kg[40] — so “no pharmacokinetic information” would be wrong, but the systemic exposure a person achieves, and whether it reaches the tumour, has not been quantified. Poor water solubility is not the same as measured low oral bioavailability, especially for a complex botanical mixture — so the honest headline is uncharacterised human exposure, not proven low bioavailability.
The Concentration Gap
This is dandelion's central translational limitation. The anticancer effects are demonstrated with extracts applied directly to cells at microgram-per-millilitre concentrations, or with purified constituents at micromolar concentrations, and there is no human study establishing that oral dandelion reaches those concentrations in blood or tumour tissue. Because no human oncology exposure data exist at all, the gap here is wider and less quantified than for a compound with human pharmacokinetics: the concentrations are unestablished in humans rather than measured-and-short. The one concrete handle comes from a delivery study, where encapsulating the extract lowered the concentration it needed to work — the direction formulation research is specifically trying to push.
| Benchmark | Concentration | Interpretation |
|---|---|---|
| Dandelion extract IC50 (free), liver-cancer cells | ~49 µg/mL | Concentration of unformulated extract needed to halve liver-cancer-cell viability in a dish[32] |
| Dandelion extract IC50 (chitosan nanoparticle) | ~18 µg/mL | Encapsulation lowered the effective concentration roughly threefold and raised cancer-cell selectivity[32] |
| Achievable human oral exposure | Not established | No human pharmacokinetic study measures dandelion constituent levels after an oral dose — the gap cannot be quantified[32] |
Clinical Dose Context
Traditional and supplement dandelion doses are framed for digestive and diuretic use — dried root or leaf in the range of hundreds of milligrams to a few grams daily, or equivalent tincture volumes — not for any oncology target. No oncology dosing framework exists for dandelion, and no human study defines a cancer-relevant exposure. Any comparison between a supplement dose and the preclinical work is therefore undefined: the studies used extract concentrations in a dish, not oral human doses, and the two cannot be equated without the human pharmacokinetic data that do not yet exist.
Formulation Effects
For dandelion, the distinction that actually carries evidence is not a branded formulation but the plant part and the solvent — these change which constituents are present and, with them, the biology. Enhanced-delivery work is emerging on top of that, aimed at the poor solubility of the triterpene actives.
| Part | Preparation studied | What studies showed (preclinical / cell) | Closest retail form |
|---|---|---|---|
| Taraxacum officinalethe common dandelion | |||
| Root | Aqueous, concentrated lab extract | Core “DRE” story — selective cell death in leukemia/CMML[1,2] and melanoma[3]; mitochondrial/autophagic death in pancreatic[4]; multi-pathway death in colorectal, >90% oral xenograft ↓[5]; ESCC ↓PI3K-Akt & Ras-Raf-ERK[6]; prostate xenograft ↓, enhanced mitoxantrone but not taxol[7] | Approximate — authenticated root water extract (with an extraction ratio). A plain “root 500 mg” powder is further off. |
| Root | Freeze-dried aqueous extract | HepG2/Huh7 cytotoxicity[32] | Approximate — a freeze-dried root water extract. |
| Root | Methanolic | HepG2 cytotoxicity + ↑AMPK[26] | Non-retail — methanol is a lab solvent; an ethanol tincture isn’t equivalent. |
| Root | Chitosan nanoparticle (of that extract) | NP lowered IC50 ~49→18 µg/mL vs the free extract[32] | Non-retail — a delivery construct, not a sold form. |
| Leaf | Aqueous | Slowed MCF-7 breast growth, blocked LNCaP prostate invasion (↓ERK/FAK/Src/MMP)[8]; leaf+flower antioxidant/UV protection of skin cells[28] | Approximate — leaf, ideally water-extracted — not root, not a tincture. |
| Flower | Aqueous | No growth/invasion effect (negative comparator)[8]; antioxidant/UV protection[28] | Approximate — flower tea/extract exists; weak anticancer rationale. |
| Seed | Aqueous | Selective ESCC inhibition + cisplatin sensitisation[21] | Approximate — seed extracts uncommon at retail. |
| Whole herb | 70% ethanol | A549 STAT3 suppression (↓Bcl-xL/survivin/c-Myc/Mcl-1)[19] | Approximate — a whole-herb hydroethanolic tincture resembles the solvent class. |
| Whole herb | Aqueous, fermented | Paediatric/neuroblastoma apoptosis, selective vs fibroblasts[24] | Non-retail — fermented, preparation-specific. |
| Taraxacum mongolicumPu Gong Ying / Taraxaci Herba — a different species | |||
| Leaf | Ethanol | Estrogenic — ↑MCF-7 + ERE/pS2/PR, tamoxifen-blockable[29] | Caution — the ethanolic leaf is the preparation behind the ER flag. |
| Leaf | Hot-water polysaccharide | HepG2 apoptosis + cell-cycle arrest[11] | Non-retail — isolated polysaccharide ≠ “leaf extract.” |
| Whole herb | Aqueous (with T. formosanum) | Mixed in ER+ breast — ↓MCF-7 but ↑ZR-75-1; mongolicum > formosanum vs TNBC[30] | Approximate — even aqueous Taraxacum isn’t uniformly anti-proliferative in ER+. |
| Whole herb | Ethanol (characterised) | TNBC: stemness/β-catenin[9]; TAM RAC2-NF-κB + ↓lung mets[22]; ferroptosis via NCOA4[42]; ↓IL-10/STAT3/PD-L1[43] | Approximate — T. mongolicum whole-herb ethanol extract — not T. officinale root. |
| Inulin | Purified fructan + Se-nanoparticle | HepG2/A549/HeLa; zebrafish anti-tumour/angiogenesis[20] | Non-retail — research-only construct. |
| Taraxacum coreanum | |||
| Constituent | Purified taraxinic acid | HL-60 leukemia differentiation[12] | Non-retail — isolated constituent. |
| Isolated constituentsspecies-agnostic — purified compounds, not an extract | |||
| Constituent | Purified taraxasterol | Liver/HCC/prostate/bladder/lung/pancreatic/gastric[13,15,16,17,18,25] | Non-retail — isolated-compound doses; a root supplement won’t reproduce them. |
| Constituent | Purified taraxerol | Breast ferroptosis[23] | Non-retail — isolated constituent. |
Approximate — a form you can buy roughly resembles what was studied · Non-retail — lab solvent, isolated compound, or research-only construct · Caution — the preparation behind a safety flag. A match means the identity lines up, not that the effect will — none of these has a human cancer trial.
None of the enhanced-delivery work has been tested against a human cancer endpoint, so a solubility or potency advantage in a dish cannot be assumed to translate into an oncology outcome. The practical, evidence-supported message is the part-and-solvent one: “dandelion” on a label is a family of preparations, and the aqueous root extract behind most of the anticancer research is not the same thing as an alcoholic tincture or a flower tea.
Metabolism
Dandelion's constituents follow the usual fates of their chemical classes: the triterpenes (taraxasterol, taraxerol, lupeol, amyrins) undergo hepatic oxidative and phase-II metabolism typical of lipophilic terpenoids; the phenolic acids are conjugated (glucuronidation, sulfation, methylation) like other dietary polyphenols; and the inulin-type fructans are not absorbed but fermented by colonic microbiota to short-chain fatty acids. No dedicated human mass-balance or metabolite-identification study for dandelion's anticancer constituents was identified, so the circulating species after an oral dose — and their activity in tumour tissue — are not established. This is a genuine gap, stated as such rather than filled with class-analogy specifics.
Co-Dosing Considerations
No direct human pharmacokinetic drug-interaction study for dandelion with any specific oncology drug is available. The rows below rest on mechanistic and preclinical data only, and each is flagged by the most cautious guidance that evidence supports.
Discuss whether to combine, separate, or avoid dandelion and a medication with your treating oncology team or physician.
| Flag | Interaction |
|---|---|
| Caution | Antidiabetic medicines (insulin, sulfonylureas, DPP-IV inhibitors) — theoretical/preclinical. T. officinale extracts inhibit DPP-IV in vitro and dandelion provides fermentable inulin fibre, but a clinically meaningful glucose-lowering effect of dandelion alone has not been established — the human glucose data come mainly from multi-herb formulations. Additive effects with antidiabetic medicines remain possible rather than demonstrated.[35] |
| Caution | Endocrine therapy and hormone-sensitive cancers — related Taraxacum species (T. mongolicum, T. formosanum) have shown estrogen-receptor activity and cell-line-dependent proliferative effects in ER-positive breast models. This is preclinical and not established for T. officinale, but because the direction of effect may depend on species, preparation and tumour context, caution in hormone-sensitive disease is reasonable — worth reviewing with the oncology team before combining with tamoxifen or an aromatase inhibitor.[29,30] |
| Monitor | Drug-metabolism interactions — uncertain. No clinically meaningful dandelion–drug interaction magnitude has been established in humans; the reviews describe a low-toxicity profile, which is reassuring rather than proof of no effect on drug clearance. Rather than a blanket flag on every metabolised drug, the practical step is to raise any new supplement with the treating team.[36] |
Advertisement
04 — Onset & Washout
Onset and Washout
Dandelion's two clocks are further apart than most, because the first one — how fast its constituents appear and clear in the body — has never been measured in people. Only the accumulated-effect clock is described, and only in cells and animals.
Immediate Onset
No human pharmacokinetic study describes how fast dandelion's anticancer constituents appear or clear in people — the plasma clock is simply uncharacterised.
Steady State
No repeated-dose human study establishes steady-state levels of any dandelion anticancer constituent, so continuous target engagement can't be assumed from any dosing schedule.
Accumulated Effect
Preclinical effects developed over sustained exposure — 48-hour selective killing in cells, multi-week oral dosing in the mouse tumour studies. No human timeline exists.
Dosing Pattern in Studies
Preclinical studies used daily oral or injected dosing over weeks. That describes how dandelion was studied in animals — not a recommended human regimen or a proven requirement.
Washout
How long dandelion's influence might take to clear before it stops being a relevant factor for co-administered medications.
No clinically validated washout period exists, and none can be calculated — the human clearance of dandelion's constituents is unmeasured, so a washout time cannot be derived from plasma data that does not exist.
Two Distinct Clocks
For dandelion the two clocks are especially far apart, because there is no human pharmacokinetic curve to describe the first one. The immediate, plasma clock — how fast the constituents appear and clear after a dose — is uncharacterised for dandelion's anticancer constituents in people: no single-dose human pharmacokinetic study was identified for taraxasterol, taraxerol, or the whole extract at anticancer-relevant exposures.
The accumulated, effect clock is only described preclinically. The cell and animal effects developed over sustained exposure — selective killing measured at 48 hours in vitro,[5] and multi-week oral or injected dosing in the mouse tumour studies.[5,6,17] Because the plasma clock is unmeasured, no statement can be made about when a biological effect would begin or fade in a person, or how any tissue effect relates to blood levels — that connection has simply never been measured for this plant.
Steady State and Accumulation
Not established. There is no repeated-dose human pharmacokinetic study confirming steady-state levels, accumulation, or continuous target engagement for any dandelion anticancer constituent. The preclinical studies used repeated daily dosing over their experimental windows, which describes how dandelion was administered in animals — it does not establish that daily dosing produces a sustained pathway-level effect in people, or what exposure that would require.
Dosing Pattern in Studies
The preclinical tumour studies used daily oral or intraperitoneal dosing of extract or constituent over the experimental period, typically weeks.[5,6,7,16,17] None tested a pulsed or single-dose schedule, and — because there is no human oncology study at all — there is no human dosing pattern to describe. This is how dandelion was studied in animals, not a recommended regimen, and not evidence that continuous dosing is biologically necessary.
Washout
No clinically validated dandelion washout interval can be derived for oncology from available human pharmacokinetic data. Individual constituents have animal PK (taraxasterol in rats[40]), but the human clearance of dandelion's constituents is unmeasured, so the interaction concerns that do have a mechanistic basis — the theoretical glucose effect[35] and the estrogenic signal in related species[29,30] — cannot be timed against a human plasma half-life that has not been measured. Rather than derive a washout window from data that does not exist, any timing question around dandelion and a co-administered medicine should be raised with the treating team when dandelion is started; the decision belongs to the reader's medical team.
Advertisement
05 — Safety
Safety Profile
Dandelion is generally well tolerated at culinary and traditional-supplement doses, with a long history of dietary use. Its best-documented adverse effect is allergy — it is a recognised Asteraceae contact allergen. The oncology-specific consideration that carries the most weight is its estrogenic activity in hormone-sensitive tissue. No dedicated high-dose toxicity study in a cancer context was identified.
Asteraceae (Compositae) allergy — a recognised contact allergen through its sesquiterpene lactones; people allergic to ragweed, chrysanthemum, marigold or chamomile may cross-react.
Estrogenic activity (ER-positive cancers) — related Taraxacum species (T. mongolicum, T. formosanum) showed estrogen-receptor activity and mixed proliferative effects in ER-positive breast cells. Preclinical and not shown for T. officinale, but caution in hormone-sensitive disease is reasonable.
Biliary disease / gallstones — the EMA monograph cautions against dandelion root in bile-duct obstruction, cholangitis, gallstones and other biliary disease because of its choleretic (bile-stimulating) action.
Adverse Effects and Allergy
Dandelion's best-documented adverse effect is allergy. It is a recognised contact allergen within the Asteraceae/Compositae family, whose sesquiterpene lactones are the principal sensitisers, and it appears in European regulatory reviews of herbal contact dermatitis.[33,34] People sensitised to other Asteraceae plants — ragweed, chrysanthemum, marigold, chamomile — may cross-react. Beyond allergy, dandelion's bitter, choleretic action can cause mild gastrointestinal upset or heartburn in some users, consistent with its traditional digestive use. No dedicated human toxicity study or safety monograph for high-dose supplemental dandelion in a cancer context was identified, and that absence is stated rather than read as a clean safety record.
Oncology-Specific Consideration — Estrogenic Activity (mostly a related-species signal)
Dandelion is not uniformly anti-cancer in hormone-sensitive tissue — but the cleanest estrogen evidence is from related species, not T. officinale. An ethanolic Taraxacum mongolicum extract behaved as a phytoestrogen — stimulating proliferation of estrogen-receptor-positive breast-cancer cells, raising estrogen-response-element-driven transcription and the estrogen-regulated genes pS2 and progesterone receptor, all blocked by tamoxifen, and slightly increasing uterine weight in immature rats.[29] An aqueous T. mongolicum/T. formosanum study raised one ER-positive line's proliferation while suppressing two others.[30] This runs opposite to the pro-apoptotic effect in estrogen-receptor-negative breast cells[10] and the aqueous root work, which makes the direction of effect species-, preparation- and receptor-status-dependent. These findings are preclinical and have not established that a T. officinale supplement interferes clinically with tamoxifen, aromatase inhibitors or other endocrine therapy. Because the direction of effect may depend on species, preparation and tumour context, caution in hormone-sensitive disease remains reasonable — the page's primary caution — without pretending the species-transfer question is settled.
Biliary Disease and Choleretic Caution
The European Medicines Agency's herbal monograph for dandelion root gives a concrete traditional-medicine precaution: it is not recommended in bile-duct obstruction, cholangitis, liver disease, gallstones and other biliary disease, because of its effects on bile secretion (its choleretic action).[41] This is a more authoritative and clinically concrete caution than any speculative enzyme-interaction flag. The monograph reports no medicinal-product interactions.
Pregnancy and Reproductive Safety
The EMA monograph does not recommend medicinal-dose dandelion root during pregnancy or lactation because safety has not been established in the absence of sufficient data.[41] The related-species estrogenic signal[29] reinforces caution. Avoidance during pregnancy is prudent unless specifically reviewed by a qualified clinician. Drug interactions are handled once under Co-Dosing above.
06 — Sourcing
Sourcing Guide
For dandelion, the plant part and the solvent are the biggest factors in what a product can plausibly do — an aqueous root extract is not the same thing as an alcoholic tincture or a flower tea, and the anticancer research clusters on specific preparations. Brand quality, characterisation, and how the extract was made matter more than a headline milligram figure. Our Sourcing Guide offers a curated list of products available on the retail market we found to answer those concerns.
Dandelion Sourcing Guide07 — Literature
References
Last reviewed: August 2026